JP2020524685A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020524685A5 JP2020524685A5 JP2019570520A JP2019570520A JP2020524685A5 JP 2020524685 A5 JP2020524685 A5 JP 2020524685A5 JP 2019570520 A JP2019570520 A JP 2019570520A JP 2019570520 A JP2019570520 A JP 2019570520A JP 2020524685 A5 JP2020524685 A5 JP 2020524685A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- dimethyl fumarate
- motomeko
- administration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims description 55
- LDCRTTXIJACKKU-ONEGZZNKSA-N dimethyl fumarate Chemical compound COC(=O)\C=C\C(=O)OC LDCRTTXIJACKKU-ONEGZZNKSA-N 0.000 claims description 38
- 229960004419 dimethyl fumarate Drugs 0.000 claims description 29
- 238000000034 method Methods 0.000 claims description 26
- 239000002245 particle Substances 0.000 claims description 16
- 239000011248 coating agent Substances 0.000 claims description 15
- 238000000576 coating method Methods 0.000 claims description 15
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 13
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 13
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 13
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 13
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 11
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 claims description 11
- 239000008101 lactose Substances 0.000 claims description 11
- 208000023275 Autoimmune disease Diseases 0.000 claims description 10
- 230000002757 inflammatory effect Effects 0.000 claims description 10
- 230000002496 gastric effect Effects 0.000 claims description 9
- 239000000203 mixture Substances 0.000 claims description 8
- NKHAVTQWNUWKEO-UHFFFAOYSA-N fumaric acid monomethyl ester Natural products COC(=O)C=CC(O)=O NKHAVTQWNUWKEO-UHFFFAOYSA-N 0.000 claims description 7
- NKHAVTQWNUWKEO-NSCUHMNNSA-N monomethyl fumarate Chemical compound COC(=O)\C=C\C(O)=O NKHAVTQWNUWKEO-NSCUHMNNSA-N 0.000 claims description 7
- 229940005650 monomethyl fumarate Drugs 0.000 claims description 7
- 230000036470 plasma concentration Effects 0.000 claims description 7
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims description 6
- 238000009472 formulation Methods 0.000 claims description 6
- 229920002785 Croscarmellose sodium Polymers 0.000 claims description 5
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 5
- 229960001681 croscarmellose sodium Drugs 0.000 claims description 5
- 235000012054 meals Nutrition 0.000 claims description 5
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 5
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 claims description 4
- 201000004681 Psoriasis Diseases 0.000 claims description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 4
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 claims description 4
- 208000027866 inflammatory disease Diseases 0.000 claims description 4
- 239000000314 lubricant Substances 0.000 claims description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical group [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 4
- 201000006417 multiple sclerosis Diseases 0.000 claims description 4
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 4
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 2
- 208000011231 Crohn disease Diseases 0.000 claims description 2
- 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 claims description 2
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 claims description 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 2
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 2
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 claims description 2
- 229920001577 copolymer Polymers 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 201000010901 lateral sclerosis Diseases 0.000 claims description 2
- 235000019359 magnesium stearate Nutrition 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 208000005264 motor neuron disease Diseases 0.000 claims description 2
- 210000003205 muscle Anatomy 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 claims description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 2
- 239000000377 silicon dioxide Substances 0.000 claims description 2
- 239000000454 talc Substances 0.000 claims description 2
- 229910052623 talc Inorganic materials 0.000 claims description 2
- 208000021386 Sjogren Syndrome Diseases 0.000 claims 1
- 208000002552 acute disseminated encephalomyelitis Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 239000001530 fumaric acid Substances 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 206010028417 myasthenia gravis Diseases 0.000 claims 1
- 230000000291 postprandial effect Effects 0.000 claims 1
- 241001465754 Metazoa Species 0.000 description 2
- 206010028372 Muscular weakness Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 201000002491 encephalomyelitis Diseases 0.000 description 1
- 230000036473 myasthenia Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1710114.8 | 2017-06-23 | ||
| GBGB1710114.8A GB201710114D0 (en) | 2017-06-23 | 2017-06-23 | Pharmaceutical compositions |
| EP17382402 | 2017-06-27 | ||
| EP17382402.0 | 2017-06-27 | ||
| PCT/EP2018/066970 WO2018234584A1 (en) | 2017-06-23 | 2018-06-25 | Pharmaceutical compositions comprising dimethyl fumarate |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020524685A JP2020524685A (ja) | 2020-08-20 |
| JP2020524685A5 true JP2020524685A5 (enExample) | 2021-08-05 |
| JP7308763B2 JP7308763B2 (ja) | 2023-07-14 |
Family
ID=62791731
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019570520A Active JP7308763B2 (ja) | 2017-06-23 | 2018-06-25 | フマル酸ジメチルを含む医薬組成物 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US11602515B2 (enExample) |
| EP (1) | EP3641736A1 (enExample) |
| JP (1) | JP7308763B2 (enExample) |
| KR (1) | KR20200018458A (enExample) |
| CN (1) | CN110636838A (enExample) |
| AU (1) | AU2018287442A1 (enExample) |
| CA (1) | CA3059293A1 (enExample) |
| MA (1) | MA49448A (enExample) |
| WO (1) | WO2018234584A1 (enExample) |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19853487A1 (de) | 1998-11-19 | 2000-05-25 | Fumapharm Ag Muri | Verwendung von Dialkylfumaraten |
| DE10101307A1 (de) | 2001-01-12 | 2002-08-01 | Fumapharm Ag Muri | Fumarsäurederivate als NF-kappaB-Inhibitor |
| PL2316430T3 (pl) | 2004-10-08 | 2012-11-30 | Forward Pharma As | Kompozycje farmaceutyczne o kontrolowanym uwalnianiu, zawierające ester kwasu fumarowego |
| JP5149160B2 (ja) | 2005-04-28 | 2013-02-20 | ワイス・エルエルシー | ミクロ化タナプロゲットおよびこれを含む組成物 |
| WO2007042034A1 (en) | 2005-10-07 | 2007-04-19 | Aditech Pharma Ab | Controlled release pharmaceutical compositions comprising a fumaric acid ester |
| EP1940382A2 (en) | 2005-10-07 | 2008-07-09 | Aditech Pharma AB | Combination therapy with fumaric acid esters for the treatment of autoimmune and/or inflammatory disorders |
| WO2009118764A1 (en) | 2008-03-28 | 2009-10-01 | Panacea Biotec Limited | Pharmaceutical composition comprising diclofenac and paracetamol |
| WO2010079222A1 (en) | 2009-01-09 | 2010-07-15 | Forward Pharma A/S | Pharmaceutical formulation comprising one or more fumaric acid esters in an erosion matrix |
| EP2379062A1 (en) | 2009-01-09 | 2011-10-26 | Forward Pharma A/S | Pharmaceutical composition comprising one or more fumaric acid esters |
| EP3318249A1 (en) | 2009-04-29 | 2018-05-09 | Biogen MA Inc. | Dimethyl fumarate dosage regimens for the treatment of multiple sclerosis |
| AR086647A1 (es) | 2011-06-03 | 2014-01-15 | Hoffmann La Roche | Metodos para tratar el mesotelioma con un compuesto inhibidor de la pi3k |
| JP6189333B2 (ja) | 2012-02-07 | 2017-08-30 | バイオジェン エムエー インコーポレーテッド | フマル酸ジメチルを含有する医薬組成物 |
| NZ720287A (en) | 2013-12-12 | 2020-05-29 | Almirall Sa | Pharmaceutical compositions comprising dimethyl fumarate |
| MA40982A (fr) * | 2014-11-19 | 2017-09-26 | Biogen Ma Inc | Formulation de bille pharmaceutique comprenant du fumarate de diméthyle |
-
2018
- 2018-06-25 AU AU2018287442A patent/AU2018287442A1/en not_active Abandoned
- 2018-06-25 CN CN201880032458.1A patent/CN110636838A/zh active Pending
- 2018-06-25 CA CA3059293A patent/CA3059293A1/en active Pending
- 2018-06-25 MA MA049448A patent/MA49448A/fr unknown
- 2018-06-25 KR KR1020197037153A patent/KR20200018458A/ko not_active Ceased
- 2018-06-25 WO PCT/EP2018/066970 patent/WO2018234584A1/en not_active Ceased
- 2018-06-25 US US16/625,092 patent/US11602515B2/en active Active
- 2018-06-25 EP EP18735535.9A patent/EP3641736A1/en active Pending
- 2018-06-25 JP JP2019570520A patent/JP7308763B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2509046B2 (ja) | 胆汁酸およびその塩を含有する経口投与用の放出制御型胃液耐性製剤 | |
| JP2015506377A5 (enExample) | ||
| JP2019515884A5 (enExample) | ||
| EP2043615A2 (en) | Pharmaceutical compositions comprising levetiracetam | |
| CN1215991A (zh) | 霉酚酸盐的包有肠溶衣的药物组合物 | |
| CN101031305A (zh) | 类风湿性关节炎的预防和/或治疗药物 | |
| AU2015326196B2 (en) | Pharmaceutical composition for treating ulcerative colitis | |
| US7071222B2 (en) | Preparation containing a combination of 5-methylisoxazole-4-carboxylic acid-(4-trifluoromethyl)-anilide and N-(4-trifluoromethylphenyl)2-cyano-3-hydroxycrotonic acid amide | |
| JP2021504313A (ja) | 慢性炎症性疾患および／または自己免疫疾患の予防または治療における使用のためのビドフルジムス（Ｖｉｄｏｆｌｕｄｉｍｕｓ）の投与レジメン | |
| CN111918646B (zh) | 延迟释放去铁酮片剂及其使用方法 | |
| HU202102B (en) | Process for producing oral pharmaceutical compositions with controlled release of the active components | |
| CN1211081C (zh) | 坦洛新在制备神经原性膀胱伴有的排尿障碍治疗剂上的应用 | |
| JP7224067B2 (ja) | フマル酸ジメチルを含有する腸溶性錠剤 | |
| JP2024095711A (ja) | 可溶性グアニル酸シクラーゼ活性化薬としてのアルコキシピラゾール | |
| JPWO2021111124A5 (enExample) | ||
| OA11836A (en) | Controlled release formulation for treating COPD. | |
| JP2025506890A (ja) | 治療用の化合物、製剤、およびそれらの使用 | |
| JP2016528171A5 (enExample) | ||
| JP2020524685A5 (enExample) | ||
| EP0787491B1 (en) | Preventive and remedy for type i allergic diseases | |
| JPH0140009B2 (enExample) | ||
| JPWO2019236757A5 (enExample) | ||
| US11576871B2 (en) | Formulations of cysteamine and cystamine | |
| CN106714798B (zh) | 血脂异常症治疗剂 | |
| JPH05194228A (ja) | ダピプラゾール含有経口投与用固体医薬組成物 |